Institute of Medical Biology (IMB), 8A Biomedical Grove, # 06-06 Immunos, Level 5, Room # 5.04, Singapore, 138648, Singapore,
Adv Biochem Eng Biotechnol. 2009;114:201-35. doi: 10.1007/10_2008_27.
Stem cells have been envisioned to become an unlimited cell source for regenerative medicine. Notably, the interest in stem cells lies beyond direct therapeutic applications. They might also provide a previously unavailable source of valuable human cell types for screening platforms, which might facilitate the development of more efficient and safer drugs. The heterogeneity of stem cell types as well as the numerous areas of application suggests that differential processes are mandatory for their in vitro culture. Many of the envisioned applications would require the production of a high number of stem cells and their derivatives in scalable, well-defined and potentially clinical compliant manner under current good manufacturing practice (cGMP). In this review we provide an overview on recent strategies to develop bioprocesses for the expansion, differentiation and enrichment of stem cells and their progenies, presenting examples for adult and embryonic stem cells alike.
干细胞被视为再生医学中一种无限的细胞来源。值得注意的是，人们对干细胞的兴趣不仅在于直接的治疗应用。它们还可能为筛选平台提供以前无法获得的有价值的人类细胞类型，从而促进更有效和更安全的药物的开发。干细胞类型的异质性以及众多的应用领域表明，它们的体外培养需要不同的过程。许多预想的应用都需要以可扩展、定义明确且具有潜在临床一致性的方式，根据现行良好生产规范（cGMP），以大量且具有高纯度的方式生产干细胞及其衍生物。在这篇综述中，我们概述了最近开发用于干细胞及其后代扩增、分化和富集的生物工艺的策略，为成体和胚胎干细胞都提供了实例。
